ATE531729T1 - Kdr-peptide und diese enthaltende impfstoffe - Google Patents

Kdr-peptide und diese enthaltende impfstoffe

Info

Publication number
ATE531729T1
ATE531729T1 AT08018875T AT08018875T ATE531729T1 AT E531729 T1 ATE531729 T1 AT E531729T1 AT 08018875 T AT08018875 T AT 08018875T AT 08018875 T AT08018875 T AT 08018875T AT E531729 T1 ATE531729 T1 AT E531729T1
Authority
AT
Austria
Prior art keywords
peptides
amino acid
vaccines containing
seq
acid sequence
Prior art date
Application number
AT08018875T
Other languages
English (en)
Inventor
Hideaki Tahara
Satoshi Wada
Takuya Tsunoda
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Application granted granted Critical
Publication of ATE531729T1 publication Critical patent/ATE531729T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464409—Vascular endothelial growth factor receptors [VEGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
AT08018875T 2002-09-12 2003-09-12 Kdr-peptide und diese enthaltende impfstoffe ATE531729T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002267285 2002-09-12
JP2003062003 2003-03-07
JP2003167042 2003-06-11

Publications (1)

Publication Number Publication Date
ATE531729T1 true ATE531729T1 (de) 2011-11-15

Family

ID=31998762

Family Applications (2)

Application Number Title Priority Date Filing Date
AT08018875T ATE531729T1 (de) 2002-09-12 2003-09-12 Kdr-peptide und diese enthaltende impfstoffe
AT03795432T ATE432291T1 (de) 2002-09-12 2003-09-12 Kdr-peptide und diese enthaltende impfstoffe

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT03795432T ATE432291T1 (de) 2002-09-12 2003-09-12 Kdr-peptide und diese enthaltende impfstoffe

Country Status (14)

Country Link
US (5) US7514084B2 (de)
EP (11) EP2267021B1 (de)
JP (3) JP3971769B2 (de)
CN (5) CN101139393B (de)
AT (2) ATE531729T1 (de)
AU (1) AU2003264419A1 (de)
CY (2) CY1109463T1 (de)
DE (1) DE60327786D1 (de)
DK (6) DK2261249T3 (de)
ES (2) ES2327040T3 (de)
HK (7) HK1124077A1 (de)
PT (2) PT2014678E (de)
SI (2) SI1548032T1 (de)
WO (1) WO2004024766A1 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2327040T3 (es) * 2002-09-12 2009-10-23 Oncotherapy Science, Inc. Peptidos kdr y vacunas que los contienen.
US9090673B2 (en) * 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
JP4628208B2 (ja) * 2004-08-10 2011-02-09 オンコセラピー・サイエンス株式会社 Ｃｘａｄｒｌ１またはｇｃｕｄ１タンパク質を発現する胃癌または結腸直腸癌の治療のためのペプチドワクチン
PL2325306T3 (pl) * 2005-02-25 2014-07-31 Oncotherapy Science Inc Szczepionki peptydowe do zastosowania w nowotworach płuc, wykazujących ekspresję polipeptydów TTK, URLC10 lub KOC1
PL2289533T3 (pl) 2005-02-28 2014-02-28 Oncotherapy Science Inc Peptydy epitopowe pochodzące z receptora 1 naczyniowego śródbłonkowego czynnika wzrostu oraz szczepionki zawierające takie peptydy
US20060234941A1 (en) 2005-04-15 2006-10-19 The Gov. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis
CN101283279A (zh) 2005-07-29 2008-10-08 肿瘤疗法科学股份有限公司 以cdca1-kntc2复合物为靶标的筛选和nsclc治疗方法
WO2007070660A2 (en) 2005-12-13 2007-06-21 President And Fellows Of Harvard College Scaffolds for cell transplantation
ES2657480T3 (es) 2006-08-11 2018-03-05 Life Sciences Research Partners Vzw Péptidos inmunogénicos y su uso en trastornos inmunitarios
TWI441648B (zh) * 2007-01-03 2014-06-21 Oncotherapy Science Inc Ｆｏｘｐ３胜肽疫苗
AU2008215432B2 (en) * 2007-02-16 2013-03-21 Oncotherapy Science, Inc. Vaccine therapy for choroidal neovascularization
TW201425333A (zh) * 2007-04-11 2014-07-01 Oncotherapy Science Inc 腫瘤血管內皮標誌８胜肽及包含此胜肽之疫苗
TW200908998A (en) * 2007-06-27 2009-03-01 Oncotherapy Science Inc Compositions and methods of treating cancer
CN101835892B (zh) 2007-08-20 2013-11-06 肿瘤疗法科学股份有限公司 Cdca1肽和包含cdca1肽的药剂
JP5555952B2 (ja) 2007-08-20 2014-07-23 オンコセラピー・サイエンス株式会社 Ｆｏｘｍ１ペプチドおよびこれを含む薬剤
TWI436775B (zh) * 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌
TW200932260A (en) * 2007-11-28 2009-08-01 Oncotherapy Science Inc STAT3 epitope peptides
CN102006891B (zh) 2008-02-13 2017-04-26 哈佛学院董事会 连续的细胞程序化装置
EP2623125A1 (de) 2008-02-14 2013-08-07 Life Sciences Research Partners VZW Beseitigung von Immunantworten an virale Vektoren
AU2009214042B2 (en) 2008-02-14 2014-02-13 Katholieke Universiteit Leuven Immunotherapy targeting intracellular pathogens
ES2627882T3 (es) 2008-02-14 2017-07-31 Life Sciences Research Partners Vzw Control inmunogénico de tumores y células tumorales
WO2009101207A1 (en) 2008-02-14 2009-08-20 Life Sciences Research Partners Vzw Cd4+ t-cells with cytolytic properties
TW201000119A (en) * 2008-06-10 2010-01-01 Oncotherapy Science Inc MYBL2 epitope peptides and vaccines containing the same
TWI526219B (zh) * 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
EP2350118B1 (de) 2008-09-19 2016-03-30 Nektar Therapeutics Kohlenhydratbasisierte polymere zur wirkstoffabgabe und konjugate davon
UA102274C2 (ru) 2008-10-22 2013-06-25 Онкотерапі Саєнс, Інк. Эпитопный пептид rab6kifl/kif20a и вакцины, которые его содержат
TWI539160B (zh) * 2008-12-05 2016-06-21 腫瘤療法 科學股份有限公司 Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗
TW201032820A (en) * 2008-12-16 2010-09-16 Oncotherapy Science Inc ELOVL7 epitope peptides and vaccines containing the same
CA2747686A1 (en) * 2008-12-24 2010-07-01 Oncotherapy Science, Inc. C1orf59 peptides and vaccines including the same
EP2684957A2 (de) 2009-01-08 2014-01-15 International Institute of Cancer Immunology, Inc. Doppelsträngige siRNA gegen das Krebsantigen eEF2
US20120107333A1 (en) * 2009-03-04 2012-05-03 Oncotherapy Science, Inc. Vangl1 peptides and vaccines including the same
EP2408913B1 (de) 2009-03-18 2016-12-14 Oncotherapy Science, Inc. Neil3-peptide und diese enthaltende impfstoffe
TW201100090A (en) * 2009-04-01 2011-01-01 Oncotherapy Science Inc C6orf167 peptides and vaccines containing the same
TWI507204B (zh) * 2009-05-26 2015-11-11 Oncotherapy Science Inc Ｃｄｃ４５ｌ胜肽與含此胜肽之疫苗
TW201109029A (en) * 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization
JP5926180B2 (ja) * 2009-07-31 2016-05-25 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 寛容原性療法のための細胞のプログラミングの方法
TW201200525A (en) * 2009-12-04 2012-01-01 Oncotherapy Science Inc MYBL2 peptides and vaccines containing the same
TW201136604A (en) 2009-12-14 2011-11-01 Oncotherapy Science Inc TMEM22 peptides and vaccines including the same
CN102115492B (zh) * 2010-01-05 2013-03-06 中国农业科学院北京畜牧兽医研究所 血管内皮生长因子受体部分多肽及其应用
CA2792910A1 (en) 2010-03-11 2011-09-15 Yusuke Nakamura Hjurp peptides and vaccines including the same
TW201134480A (en) * 2010-04-08 2011-10-16 Oncotherapy Science Inc CLUAP1 peptides and vaccines including the same
JP2013523084A (ja) * 2010-04-09 2013-06-17 オンコセラピー・サイエンス株式会社 Ｃｄｃａ５ペプチドおよびそれを含むワクチン
TW201211250A (en) * 2010-09-07 2012-03-16 Oncotherapy Science Inc VANGL1 peptides and vaccines including the same
PT2624873T (pt) 2010-10-06 2020-03-04 Harvard College Hidrogéis injectáveis formadores de poros para terapias celulares à base de materiais
US10023847B2 (en) 2010-11-25 2018-07-17 Imnate Sarl Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination
TWI618541B (zh) 2010-12-02 2018-03-21 腫瘤療法 科學股份有限公司 Ｔｏｍｍ３４胜肽與含此胜肽之疫苗
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
CN104168917A (zh) 2012-03-09 2014-11-26 肿瘤疗法科学股份有限公司 含有肽的医药组合物
ES2773895T3 (es) 2012-04-16 2020-07-15 Harvard College Composiciones de sílice mesoporosa para modular las respuestas inmunitarias
WO2013168820A1 (ja) 2012-05-11 2013-11-14 公益財団法人微生物化学研究会 抗ｃｘａｄｒ抗体
EP2872532A4 (de) 2012-07-10 2016-04-13 Oncotherapy Science Inc Cdca1-epitoppeptide für th1-zellen und impfstoffe damit
WO2014087626A1 (en) * 2012-12-04 2014-06-12 Oncotherapy Science, Inc. Sema5b peptides and vaccines containing the same
US9932396B2 (en) 2013-02-08 2018-04-03 Medical & Biological Laboratories Co., Ltd. Antibody against human NRG1 protein
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
JP2017042047A (ja) * 2013-12-06 2017-03-02 オンコセラピー・サイエンス株式会社 Ｖｅｇｆｒ２由来ペプチドおよびそれを含むワクチン
EP3137105A4 (de) 2014-04-30 2017-12-27 President and Fellows of Harvard College Kombinationsimpfstoffvorrichtungen und -verfahren zur abtötung von krebszellen
EP3250250A4 (de) 2015-01-30 2019-05-22 President and Fellows of Harvard College Peritumorale und intratumorale materialien zur krebstherapie
WO2016129335A1 (ja) * 2015-02-09 2016-08-18 株式会社ライフアートビレッジ 免疫細胞療法のためのペプチドスクリーニング方法
CN107708756A (zh) 2015-04-10 2018-02-16 哈佛学院院长等 免疫细胞捕获装置及其制备和使用方法
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
EP3939606A3 (de) 2015-09-25 2022-04-20 ImCyse SA Verbesserte verfahren und verbindungen zur beseitigung von immunreaktionen auf therapeutische mittel
CN105200010B (zh) * 2015-10-15 2019-02-12 首都医科大学附属北京佑安医院 艾滋病感染者hla-a2特异性ctl细胞的体外培养方法及其专用培养基
EP3411475A4 (de) 2016-02-06 2019-09-11 President and Fellows of Harvard College Rekapitulation der hämatopoietischen nische zur wiederherstellung der immunität
IL262286B2 (en) 2016-04-19 2023-12-01 Imcyse Sa Novel immunogenic peptides that bind CD1D
AU2017295704B2 (en) 2016-07-13 2023-07-13 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
JP7168228B2 (ja) * 2017-05-19 2022-11-09 慶應義塾 脳神経疾患に対するペプチドワクチン及びペプチドワクチン組成物
CN111363026B (zh) * 2020-03-31 2022-03-25 浙江省中医院、浙江中医药大学附属第一医院（浙江省东方医院） 一种增强抗原多肽亲和力和稳定性的方法
KR20220022021A (ko) * 2020-08-14 2022-02-23 서울대학교산학협력단 B형 간염 바이러스 유래 폴리펩티드를 포함하는 암의 예방 또는 치료용 약학적 조성물

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861301A (en) 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
US6222012B1 (en) 1992-08-31 2001-04-24 Ludwig Institute For Cancer Research Isolated nonapeptides presented by HLA molecules, and uses thereof
CN1173991C (zh) * 1992-11-13 2004-11-03 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k-1
CA2158745C (en) 1993-03-25 2007-06-19 Richard L. Kendall Inhibitor of vascular endothelial cell growth factor
CA2225553A1 (en) 1995-08-03 1997-02-20 Rijksuniversiteit Te Leiden Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6080728A (en) * 1996-07-16 2000-06-27 Mixson; A. James Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
US5942428A (en) * 1996-08-21 1999-08-24 Sugen, Inc. Crystals of the tyrosine kinase domain of non-insulin receptor tyrosine kinases
DE19638745C2 (de) * 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
JP3837748B2 (ja) * 1997-01-17 2006-10-25 東亞合成株式会社 Ｖｅｇｆ結合性ポリペプチド
WO1998058053A1 (en) * 1997-06-18 1998-12-23 Merck & Co., Inc. Human receptor tyrosine kinase, kdr
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
CN1284083A (zh) * 1997-12-05 2001-02-14 伊东恭悟 肿瘤抗原肽衍生物
WO1999040118A1 (fr) * 1998-02-04 1999-08-12 Kyowa Hakko Kogyo Co., Ltd. Anticorps diriges contre le recepteur kdr humain du vegf
GB9804121D0 (en) * 1998-02-26 1998-04-22 Cancer Res Campaign Tech Anti-angiogenic vaccines: materials and methods relating thereto
AU3850299A (en) * 1998-05-20 1999-12-06 Kyowa Hakko Kogyo Co. Ltd. Vegf activity inhibitors
WO1999067288A1 (fr) 1998-06-25 1999-12-29 Sumitomo Pharmaceuticals Company, Limited Peptides d'antigenes tumoraux provenant de la cyclophiline b
AU6600400A (en) * 1999-08-13 2001-03-13 Crucell Holland B.V. Methods and means for inhibiting angiogenesis
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
JP2002267285A (ja) 2001-03-12 2002-09-18 Denso Corp 冷房冷蔵装置
JP4068371B2 (ja) 2001-06-13 2008-03-26 株式会社トプコン 手術用顕微鏡
JP3640084B2 (ja) 2001-11-30 2005-04-20 日本電気株式会社 測位機能を搭載した携帯電話端末
CU23178A1 (es) 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
ES2327040T3 (es) * 2002-09-12 2009-10-23 Oncotherapy Science, Inc. Peptidos kdr y vacunas que los contienen.
EP1539157B1 (de) 2002-09-18 2013-08-21 Trustees Of The University Of Pennsylvania Rapamycin zur Verwendung in der Hemmung oder Vorbeugung der choroidalen Neovaskularisation
PL2289533T3 (pl) 2005-02-28 2014-02-28 Oncotherapy Science Inc Peptydy epitopowe pochodzące z receptora 1 naczyniowego śródbłonkowego czynnika wzrostu oraz szczepionki zawierające takie peptydy
AU2008215432B2 (en) 2007-02-16 2013-03-21 Oncotherapy Science, Inc. Vaccine therapy for choroidal neovascularization
TWI436775B (zh) 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌

Also Published As

Publication number Publication date
EP1548032B1 (de) 2009-05-27
SI2014678T1 (sl) 2012-03-30
CY1113379T1 (el) 2016-06-22
EP2261248A2 (de) 2010-12-15
DK1548032T3 (da) 2009-08-17
EP2261249A2 (de) 2010-12-15
CN101139392A (zh) 2008-03-12
JP4185143B2 (ja) 2008-11-26
EP2270041A3 (de) 2011-02-16
EP2014678B1 (de) 2011-11-02
US20100215676A1 (en) 2010-08-26
EP2267023A3 (de) 2011-02-16
EP2261247A2 (de) 2010-12-15
HK1124077A1 (en) 2009-07-03
AU2003264419A1 (en) 2004-04-30
CN101139393B (zh) 2010-11-24
EP2261247A3 (de) 2011-02-16
EP2267023A2 (de) 2010-12-29
EP2261249A3 (de) 2011-02-16
EP2267023B1 (de) 2015-02-11
CN103073620A (zh) 2013-05-01
CN101139393A (zh) 2008-03-12
HK1151032A1 (en) 2012-01-20
US8574586B2 (en) 2013-11-05
PT1548032E (pt) 2009-08-13
DE60327786D1 (de) 2009-07-09
CN103073620B (zh) 2014-12-10
ATE432291T1 (de) 2009-06-15
CN1694901A (zh) 2005-11-09
HK1125659A1 (en) 2009-08-14
EP1548032B9 (de) 2009-10-28
US20060216301A1 (en) 2006-09-28
DK2014678T3 (da) 2012-02-06
EP2270042A2 (de) 2011-01-05
ES2375299T3 (es) 2012-02-28
DK2267023T3 (en) 2015-02-23
EP2270042B1 (de) 2015-01-14
EP1548032A4 (de) 2006-03-01
JP4185147B2 (ja) 2008-11-26
ES2327040T3 (es) 2009-10-23
EP2014679B1 (de) 2010-05-05
EP2261248A3 (de) 2011-02-16
CN101139392B (zh) 2012-12-26
EP2014679A1 (de) 2009-01-14
EP1548032A1 (de) 2005-06-29
JP3971769B2 (ja) 2007-09-05
US20090252752A1 (en) 2009-10-08
EP2267022A2 (de) 2010-12-29
DK2267022T3 (en) 2015-02-23
CN100352843C (zh) 2007-12-05
EP2267021A3 (de) 2011-02-16
HK1151036A1 (en) 2012-01-20
DK2267021T3 (en) 2015-03-30
PT2014678E (pt) 2012-01-05
HK1151039A1 (en) 2012-01-20
EP2267021B1 (de) 2015-02-18
HK1151037A1 (en) 2012-01-20
EP2267021A2 (de) 2010-12-29
EP2014678A3 (de) 2009-03-25
US8574585B2 (en) 2013-11-05
HK1151038A1 (en) 2012-01-20
JP2007277251A (ja) 2007-10-25
DK2261249T3 (en) 2015-02-16
JPWO2004024766A1 (ja) 2006-01-26
US7695720B2 (en) 2010-04-13
US7514084B2 (en) 2009-04-07
EP2014678A2 (de) 2009-01-14
EP2267022B1 (de) 2015-02-11
EP2270042A3 (de) 2011-02-16
EP2261249B1 (de) 2015-02-11
EP2270041A2 (de) 2011-01-05
EP2261248B1 (de) 2015-02-18
US20120328636A1 (en) 2012-12-27
US8206719B2 (en) 2012-06-26
WO2004024766A1 (ja) 2004-03-25
EP2267022A3 (de) 2011-02-16
EP2270041B1 (de) 2015-02-25
CY1109463T1 (el) 2014-08-13
JP2007191485A (ja) 2007-08-02
US20130028923A1 (en) 2013-01-31
SI1548032T1 (sl) 2009-10-31
CN103951745A (zh) 2014-07-30

Similar Documents

Publication Publication Date Title
ATE531729T1 (de) Kdr-peptide und diese enthaltende impfstoffe
WO2006090810A3 (en) Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides
IL162917A0 (en) A lysin from bacteriophage and pharmaceutical compositions containing the same
DK2289533T3 (da) Epitoppeptider afledt af karendothelvækstfaktorreceptor-1 samt vacciner indeholdende disse peptider
DE69426121D1 (de) Gen grb3-3, variante und ihre verwendungen
DE60336353D1 (de) Rekombinantes protein mit krebsunterdrückender wirkung, sein codierendes gen und seine verwendung
DE69939379D1 (de) Hemmstoff zur diagnose und behandlung von haemophilia a patienten
RU2006119452A (ru) Рекомбинантный белок, обладающий противораковым действием, кодирующий его ген и его применение
ATE417066T1 (de) Modifizierte cdna für hohe expressionsniveaus von faktor viii und dessen derivaten
EP2370454A4 (de) Wdrpuh-epitop-peptide und diese enthaltende impfstoffe
DE10394174D2 (de) Peptide mit hohem Cysteingehalt